Celbopag 25mg Tablet

About

Celbopag 25mg Tablet is an oral thrombopoietin receptor agonist (TPO-RA) designed to stimulate the production of platelets in the bone marrow. It is primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to previous treatments, and for severe aplastic anemia (SAA) in patients who are refractory to immunosuppressive therapy. The drug functions by binding to and activating the thrombopoietin receptor on the surface of megakaryocytes and their progenitor cells. This activation mimics the action of endogenous thrombopoietin, leading to increased proliferation, differentiation, and maturation of megakaryocytes, ultimately resulting in a dose-dependent increase in platelet count. By effectively raising and maintaining platelet levels, Celbopag significantly reduces the risk of bleeding episodes and the need for platelet transfusions, thereby improving the clinical management and quality of life for affected individuals.

Uses

• Treatment of chronic immune thrombocytopenia (ITP).
• Management of severe aplastic anemia (SAA).
• Used in patients who have had an insufficient response to other treatments.
• To reduce the need for platelet transfusions.

Directions For Use

Take the tablet orally once daily on an empty stomach, at least one hour before or two hours after meals.

Avoid taking with dairy products, calcium-fortified juices, or antacids containing polyvalent cations.

Benefits

• Effectively increases platelet counts.
• Reduces the risk of bleeding in thrombocytopenic patients.
• Oral administration for convenience.
• Can improve quality of life by reducing symptoms.
• Offers an alternative for patients refractory to other therapies.
• May reduce the need for platelet transfusions.

Side Effects

• Nausea
• Diarrhea
• Upper respiratory tract infection
• Fatigue
• Headache
• Muscle pain
• Joint pain
• Elevated liver enzymes
• Thrombotic/thromboembolic events (blood clots)
• Bone marrow reticulin formation
• Cataracts (rare)
• Skin rash

Safety Measures

• Alcohol - No specific interaction, but excessive alcohol consumption can affect liver function, which should be monitored while on Celbopag.
• Pregnancy - Use only if the potential benefit justifies the potential risk to the fetus. Animal studies have shown reproductive toxicity.
• Breastfeeding - Not recommended during breastfeeding due to potential for serious adverse reactions in the breastfed infant.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary. Regular monitoring of liver function tests is crucial.
• Kidney - Use with caution in patients with renal impairment; dose adjustments may be necessary.
• Lung - No specific precautions for lung conditions, but monitor for any unusual respiratory symptoms as part of general health assessment.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.